Published in Cancer Res on June 15, 2002
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04
Role of osteopontin in tumour progression. Br J Cancer (2004) 2.65
Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol (2008) 1.83
Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol (2004) 1.75
Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer (2007) 1.40
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol (2006) 1.30
Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis (2006) 1.30
Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res (2004) 1.27
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis (2006) 1.26
Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer (2006) 1.26
The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol (2009) 1.19
Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis (2003) 1.18
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol (2006) 1.17
Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal (2011) 1.17
The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2006) 1.14
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis (2003) 1.13
Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res (2008) 1.13
Matricellular proteins: a sticky affair with cancers. J Oncol (2012) 1.10
Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer (2010) 1.08
OPN -Revisited. J Clin Diagn Res (2015) 1.05
Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res (2003) 1.04
Osteopontin and colon cancer progression. Clin Exp Metastasis (2003) 1.04
Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol (2010) 1.01
KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch (2007) 0.98
Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem (2011) 0.97
Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol (2003) 0.96
Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med (2009) 0.95
Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am J Pathol (2011) 0.95
Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol (2010) 0.94
Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol (2008) 0.93
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci (2012) 0.92
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res (2011) 0.92
Homing of cancer cells to the bone. Cancer Microenviron (2011) 0.92
CBX7 modulates the expression of genes critical for cancer progression. PLoS One (2014) 0.90
Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer (2011) 0.90
Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer (2008) 0.89
Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem (2012) 0.88
Studying non-mammalian models? Not a fool's ERRand! Trends Endocrinol Metab (2006) 0.88
Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol (2012) 0.87
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res (2014) 0.87
Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol (2007) 0.86
The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer (2015) 0.86
Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer (2004) 0.85
Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS One (2012) 0.84
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer (2011) 0.84
Myeloma cell-derived Runx2 promotes myeloma progression in bone. Blood (2015) 0.83
Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection. J Cancer Res Clin Oncol (2015) 0.83
Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer (2010) 0.83
Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J Cancer Res Clin Oncol (2009) 0.83
Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer (2010) 0.83
Nuclear osteopontin-c is a prognostic breast cancer marker. Br J Cancer (2015) 0.82
Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim Biophys Acta (2012) 0.82
Prognostic value of osteopontin expression in breast cancer: A meta-analysis. Mol Clin Oncol (2014) 0.81
Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett (2013) 0.80
Inhibition of osteopontin dependent carcinogenesis. J Cancer Res Clin Oncol (2008) 0.80
Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann Surg Oncol (2012) 0.79
Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clin Exp Metastasis (2012) 0.79
Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res (2015) 0.78
Structure and function of the solid tumor niche. Front Biosci (Schol Ed) (2012) 0.78
Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc (2012) 0.77
Inhibition of breast cancer cell adhesion and bone metastasis by the extracellular adherence protein of Staphylococcus aureus. Biochem Biophys Res Commun (2007) 0.77
Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer. Chin J Cancer Res (2011) 0.77
Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model. Surg Today (2010) 0.77
Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data. Sci Rep (2016) 0.76
S100A4 downregulates filopodia formation through increased dynamic instability. Cell Adh Migr (2011) 0.76
Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study. J Clin Diagn Res (2015) 0.76
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer (2016) 0.75
Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience (2009) 0.75
Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells. BMC Res Notes (2009) 0.75
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med (2017) 0.75
Clinical Significance of Plasma Osteopontin Level as a Biomarker of Hepatocellular Carcinoma. Gastroenterology Res (2013) 0.75
High Glucose Accelerates Cell Proliferation and Increases the Secretion and mRNA Expression of Osteopontin in Human Pancreatic Duct Epithelial Cells. Int J Mol Sci (2017) 0.75
Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis. Biomed Res Int (2016) 0.75
Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response. Br J Cancer (2016) 0.75
Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm (2017) 0.75
Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res (2005) 1.94
Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol (2003) 1.59
Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer (2008) 1.48
Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res (2006) 1.42
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res (2003) 1.41
Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res (2006) 1.33
Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol (2002) 1.29
The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol (2009) 1.19
Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem (2004) 1.18
Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells. Biophys J (2007) 1.15
Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther (2008) 1.14
DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2008) 1.13
Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol (2002) 1.07
Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci (2013) 1.02
The basic C-terminal amino acids of calcium-binding protein S100A4 promote metastasis. Carcinogenesis (2008) 1.02
Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition. J Pathol (2011) 0.98
Self-association of calcium-binding protein S100A4 and metastasis. J Biol Chem (2009) 0.97
Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes. Oncogene (2005) 0.95
The crystal structure at 2A resolution of the Ca2+ -binding protein S100P. J Mol Biol (2003) 0.95
Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. Am J Pathol (2011) 0.95
Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol (2010) 0.94
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) (2010) 0.94
Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res (2010) 0.93
RanGTPase: a candidate for Myc-mediated cancer progression. J Natl Cancer Inst (2013) 0.93
Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am J Pathol (2002) 0.93
Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res (2011) 0.92
ATP depletion induces translocation of STIM1 to puncta and formation of STIM1-ORAI1 clusters: translocation and re-translocation of STIM1 does not require ATP. Pflugers Arch (2008) 0.92
Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Biosci Rep (2012) 0.92
Metastasis-promoting anterior gradient 2 protein has a dimeric thioredoxin fold structure and a role in cell adhesion. J Mol Biol (2012) 0.90
Asymmetric mode of Ca²⁺-S100A4 interaction with nonmuscle myosin IIA generates nanomolar affinity required for filament remodeling. Structure (2012) 0.90
Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Mol Carcinog (2009) 0.90
The C-terminal region of S100A4 is important for its metastasis-inducing properties. Oncogene (2005) 0.89
S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration. J Biol Chem (2012) 0.87
Interaction of metastasis-inducing S100A4 protein in vivo by fluorescence lifetime imaging microscopy. Eur Biophys J (2004) 0.87
Peak heart rates and sympathetic function in tetraplegic nonathletes and athletes. Med Sci Sports Exerc (2015) 0.85
Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression. Cancer Sci (2012) 0.84
Heterodimeric interaction and interfaces of S100A1 and S100P. Biochem J (2004) 0.81
The role of Pea3 group transcription factors in esophageal squamous cell carcinoma. Am J Pathol (2011) 0.81
Regarding "Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients". Breast Cancer Res Treat (2011) 0.80
Microarray analysis of suppression subtracted hybridisation libraries identifies genes associated with breast cancer progression. Cell Oncol (2010) 0.80
The human sperm head: a key for successful fertilization. J Androl (2003) 0.80
Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation. Br J Haematol (2014) 0.80
Synthesis of novel ginkgolide photoaffinity--biotin probes. Org Biomol Chem (2007) 0.79
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS One (2013) 0.79
Purification, crystallization and preliminary X-ray diffraction studies of a Ca2+-binding protein, human S100P. Acta Crystallogr D Biol Crystallogr (2002) 0.78
Molecular analysis of a collection of clinical specimens stored at 4 degrees C as an alternative to snap-freezing. Int J Oncol (2009) 0.78
No effect of arm-crank exercise on diaphragmatic fatigue or ventilatory constraint in Paralympic athletes with cervical spinal cord injury. J Appl Physiol (1985) (2010) 0.78
Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci (2010) 0.77
Identification of apolipoprotein D as a novel inhibitor of osteopontin-induced neoplastic transformation. Int J Oncol (2006) 0.77
Ran GTPase in nuclear envelope formation and cancer metastasis. Adv Exp Med Biol (2014) 0.77
Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer. Int J Exp Pathol (2003) 0.76
Neuroprotection, Plasticity Manipulation, and Regenerative Strategies to Improve Cardiovascular Function following Spinal Cord Injury. J Neurotrauma (2015) 0.76
S100A4 downregulates filopodia formation through increased dynamic instability. Cell Adh Migr (2011) 0.76
Physical exercise improves arterial stiffness after spinal cord injury. J Spinal Cord Med (2014) 0.75
Synthesis of A83586C analogs with potent anticancer and beta-catenin/ TCF4/osteopontin inhibitory effects and insights into how A83586C modulates E2Fs and pRb. Org Lett (2009) 0.75
Crystallization and preliminary crystallographic analysis of a metastasis-inducing protein, human S100A4. Acta Crystallogr D Biol Crystallogr (2001) 0.75
Boosting in Elite Athletes with Spinal Cord Injury: A Critical Review of Physiology and Testing Procedures. Sports Med (2015) 0.75
Assessing Estrogen-Induced Proliferative Response in an Endometrial Cancer Cell Line Using a Universally Applicable Methodological Guide. Int J Gynecol Cancer (2017) 0.75